Billions of dollars. Dozens of new trials. Two landmark FDA approvals. And a field expanding faster than its evidence, regulatory frameworks, and operational infrastructure can support.

Bracken's Chief Medical Officer Deepak Behera, MD and senior consultant Alexander McEwan, MB, BS, MSc, FRCPC, FSNMMI have just published a peer-reviewed review in PET Clinics that names the gaps directly — and outlines what nuclear medicine departments, clinical trial sites, and industry programs need to do about it.

If you're designing a radiopharmaceutical trial, building a theranostics program, or advising one, this is required reading. 

Read the article summary and book a meeting with our team →